GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (OSL:BGBIO) » Definitions » Gross-Profit-to-Asset %

BerGenBio ASA (OSL:BGBIO) Gross-Profit-to-Asset % : 0.00% (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. BerGenBio ASA's annualized Gross Profit for the quarter that ended in Jun. 2024 was kr0.00 Mil. BerGenBio ASA's average Total Assets over the quarter that ended in Jun. 2024 was kr176.95 Mil. Therefore, BerGenBio ASA's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 was 0.00%.


BerGenBio ASA Gross-Profit-to-Asset % Historical Data

The historical data trend for BerGenBio ASA's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BerGenBio ASA Gross-Profit-to-Asset % Chart

BerGenBio ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only 2.74 0.12 0.13 0.13 0.21

BerGenBio ASA Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.78 0.43 -

Competitive Comparison of BerGenBio ASA's Gross-Profit-to-Asset %

For the Biotechnology subindustry, BerGenBio ASA's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BerGenBio ASA's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BerGenBio ASA's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where BerGenBio ASA's Gross-Profit-to-Asset % falls into.



BerGenBio ASA Gross-Profit-to-Asset % Calculation

BerGenBio ASA's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.354/( (166.706+174.335)/ 2 )
=0.354/170.5205
=0.21 %

BerGenBio ASA's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Jun. 2024 )/( (Total Assets (Q: Mar. 2024 )+Total Assets (Q: Jun. 2024 ))/ count )
=0/( (135.433+218.47)/ 2 )
=0/176.9515
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jun. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


BerGenBio ASA Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of BerGenBio ASA's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


BerGenBio ASA Business Description

Traded in Other Exchanges
Address
Mollendalsbakken 9, Bergen, NOR, 5009
BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is d is curently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. .

BerGenBio ASA Headlines

No Headlines